TNBC is most common in premenopausal women younger than 40 years, and it has a poor prognosis, high invasiveness, high metastatic behaviour, high risk of recurrence, and lacks targeted therapies compared with hormone receptor-positive and HER2-enriched breast cancers. This evidence concerns the gene ERBB2 and breast cancer.